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ABSTRACT
The success of CD8+ T cell-based cancer immunotherapy emphasizes the importance of understanding
the mechanisms of generation of MHC-I peptide ligands and the possible pathways of tumor cell escape
from immunosurveillance. Recently, we showed that peptides generated in the nucleus during a pioneer
round of mRNA translation (pioneer translation products, or PTPs) are an important source of tumor
specific peptides which correlates with the aberrant splicing and transcription events associated with
oncogenesis. Here we show that up-regulation of PSME3 proteasome activator in cancer cells results in
increased destruction of PTP-derived peptides in the nucleus thus enabling cancer cell to subvert
immunosurveillance. These findings unveil a previously unexpected role for PSME3 in antigen processing
and identify PSME3 as a druggable target to improve the efficacy of cancer immunotherapy.
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Cellular immune responses against cancer cells expressing
non-self epitopes require the activation of CD8+ T cells by
professional antigen presenting cells (pAPCs) which take up
external peptide material and present it on their major histo-
compatibility complex class I (MHC-I) molecules as part of
a process called cross-presentation.1 The MHC-I direct and
cross-presentation pathways are fundamental processes for the
detection and elimination of cells that pose a threat to the host.
In recent years, it has been suggested that peptides that are
directly presented to the MHC-I restricted pathway are not
derived from the degradation of full-length proteins but from
so-called defective ribosomal products or DRiPs.2 In addition,
some MHC-I-bound peptides are generated by cryptic transla-
tion, which refers to polypeptides synthesized in the cell via
non-conventional translational mechanisms. These are either
peptides encoded by introns, intron/exon junctions, 5ʹ and 3ʹ
untranslated regions (UTR), alternate translational reading
frames or even fusion peptides generated by the
proteasome.3–6 These observations have led to a shift in focus
toward the notion that the degradation of full-length proteins
is not the only critical process for antigen production. More
recently, we have shown that the antigen presentation is
equivalent whether the peptide is expressed from an intron or
from an exon and is supported by so-called pioneer translation
products (PTPs),7 which are produced by a translation event
distinct from canonical translation prior to mRNA splicing.
The PTP model is appealing because it partly explains how the
immune system “tolerates” tissue-dependent alternative
splicing products. By first examining how direct presentation
applies to viral mechanisms of immune evasion, we recently
demonstrated that PTPs are also a source of peptides for the
exogenous MHC-I pathway. Indeed, PTP-derived peptides are
cross-presented by pAPCs in order to specifically activate naïve
CD8+ T cells.8 Moreover, PTPs are present in exosomes that
are engulfed by bone marrow dendritic cells (BMDCs) for
cross-presentation. Finally, PTPs purified from tumor cells
(tumor-associated PTPs or TA-PTPs) have been used in com-
bination with exosomes as a potent immune cancer vaccine.8
Polypeptides such as PTPs that enter either the endogenous
or the exogenous MHC-I pathway must be processed to fit the
MHC-I molecule binding groove to elicit an immune response.
A key player of this process is the proteolytic system of the
eukaryotic cell, the ubiquitin-proteasome system.9 Central to
this system is the proteasome, a multicatalytic complex con-
sisting of a 20S proteolytic core controlled by regulatory com-
plexes that bind to it.10,11 One of these regulatory complexes is
the 19S particle, which, along with the 20S proteolytic core,
forms the 26S proteasome that degrades ubiquitylated and
some non-ubiquitylated proteins in an ATP-dependent man-
ner. Other regulatory complexes, including the REG/PA28
family, have been shown to associate with the 20S or with
asymmetric (i.e. single 19S-capped) 26S proteasomes.12,13 The
REG family consists of three related subunits which together
form two proteasome regulatory complexes: (i) REGα/β,
a heteroheptamer formed by REGα and REGβ subunits,
located primarily in the cytoplasm; and (ii) PSME3,
a homoheptamer formed by the PSME3 subunit, located in
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the nucleus.14–16 The exact functions and mechanisms of
action of PSME3 remain elusive, as only a limited number of
proteins whose degradation is mediated or controlled by this
regulator have been described. Among them are cell cycle
regulators, including the cyclin-dependent kinase inhibitors
p21 and p16, the oncogene SRC-3 and the tumor suppressor
p53.17–20 This paradigm aligns with the proliferation-
promoting and anti-apoptotic properties of PSME3 deduced
from an analysis of KOmice and the observation that PSME3 is
overexpressed in many cancers and is often associated with
a poor prognosis.21 Moreover, other observations point to
a central role for PSME3 in intranuclear dynamics through
the regulation of (i) nuclear bodies (including nuclear speckles,
Cajal and PML bodies) and (ii) nuclear trafficking of splicing
factors.22–24 Evolutionary analyzes have shown that REGα and
REGβ appeared much later in evolution than PSME3 and
diverged concomitantly with the emergence of MHC.25
PSME3 is important for responses to genotoxic and oxidative
stress as well as the impairment of proteasome function, which
is for example the case in neurodegenerative diseases.26
Interestingly, it was shown that cellular PSME3 is massively
recruited to proteasome after nontoxic treatment with protea-
some inhibitors.27 Furthermore, a specific interactor of PSME3
has been recently identified, namely PIP30, which positively
modulates the interaction of PSME3 to the 20S proteasome
complex and alters the selectivity of the PSME3/20S protea-
some complex toward different peptides.28 We have also
recently reported that PTP levels inside the nuclear compart-
ment increased when the proteasomal system was blocked
using the highly specific proteasome inhibitor epoxomicin.7
Although many studies have demonstrated a strong link
between REGα/β and antigen production in the immune
system,29 no data are currently available suggesting a negative
or positive role for PSME3 in this process, although PSME3-
knockout MEF cells and PSME3-deficient animal models have
been produced and challenged to assess specific immune
responses.30,31 Here, we show i) an inverse correlation between
the expression of PSME3 and the presentation of different
MHC-I antigenic peptides, ii) PSME3 involvement in the pro-
cessing of different PTPs and the negative regulation of CD8+
T cell responses against cancer, iii) an increased presentation of
MHC-I PTP-derived antigens due to a downregulation of
PSME3 and iv) a tumor growth defect in-vivo of PSME3-
knockout tumors. These findings describe a mechanism by
which PSME3 negatively influences cancer immune responses
in an opposite manner compared to the other members of the
REG family.
Materials and methods
T cell hybridomas, cell culture and transfection
The SIINFEKL:Kb-specific (B3Z), the MBP:Kk-specific (MBP
CD8+) and the gp100(25-33):Kk-specific T cell reporter hybri-
domas were described previously.32–34 Human cell lines were
obtained from the American Type Culture Collection (ATCC)
and cultured according to standard culture protocols and ster-
ile technique. MRC5 (ATCC, n° CCL-171), A375 (ATCC, n°
CRL-1619), A549 (ATCC, n° CCL-185), HT29 (ATCC, n°
HTB-38) and T84 (ATCC, n° CCL-248) were cultured accord-
ing to ATCC’s protocol. The WM3526 and WM3682 were
supplied by Dr. Meenhard Herlyn and cultured as accordingly.
Once a month, mycoplasma contamination in cell cultures
was assessed using the Venor®GeM OneStep mycoplasma
detection kit (Minerva biolabs). All cells were used within
four weeks after thawing (≈10 passages). All cells were trans-
fected with different increasing amount of plasmid DNA with
a final total concentration of 1 µg of plasmid DNA along with
2 μL of JetPrime according to the manufacturer’s protocol
(Ozyme). Each plasmid is detail in the supplementary data.
No difference in growth rates was observed between WT cells
and cells overexpressing or downregulating PSME3.
Drugs
Cells were treated with different drugs: epoxomicin (Peptides
International) was used at 300 nM and cisplastin (Sigma) at 5
and 10 mg/mL.
T cell assay
Human cell lines were cotransfected with different plasmids
expressing the SL8 epitope and the Kb, Kk or Kd expression
vectors depending on the epitope tested. All CD8+T cell hybri-
domas express LacZ in response to the activation of T cell
receptors specific for the SIINFEKL peptide (Ova-
immunodominant peptide) in the context of H-2Kb MHC
class I molecules, the MBP peptide (myelin basic protein-
immunodominant peptide) in the context of H2-Kk MHC
class I molecules or the gp100(25-33) peptide in the context
of H2-Kd MHC class I molecules. For the minigene antigen
presentation assays, all cell lines were co-transfected with
0.5 µg of SL8-minigene construct and 0.5 µg of H-2Kb con-
struct for 48 h. Cancer cells were then washed twice in 1X PBS
and 105 cells were co-cultured with either 105 SL8-specific B3Z
T cell hybridoma or 105 MBP-specific T cell hybridoma for
16–20 h. Free peptide was added to cells to ensure that T-cell
assays were carried out at non-saturated conditions and that
the expression of MHC class I molecules was not affected.
Next, cells were centrifuged at 1,200 rpm for 5 min. The cells
were washed twice with 1X PBS and lysed for 5 min at room
temperature (RT) in the following buffer: 0.2% Triton X-100,
0.5 M K2HPO4, 0.5 M KH2PO4. The lysates were centrifuged at
3,000 rpm for 10 min to pellet cell debris. Next, the supernatant
was transferred into an optiplate (Packard Bioscience) and
a revelation buffer containing 40 µM methylumbelliferyl β-
D-galactopyranoside (MUG) was then added. The plate was
incubated for 3 h at RT. The activity of β-galactosidase (lumi-
nescence) was measured with FLUOstar OPTIMA (BMG
LABTECH Gmbh). The values from mock-transfected cells
were subtracted as in all the other reported T cell assay
experiments.
CRISPR/Cas9 transfection and selection
After the transfection of 1 µg of CRISPR plasmid vector, cells
were sorted 2 days later (1 cell/well). PCR andWestern blotting
were performed using the clones; selected clones were sent for
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sequencing. TOPO TA cloning (Life Technologies) was carried
out for selected clones. The CRISPR/Cas9 system was applied
to the A375 cell line, and A375 clone number 11 was generated
and designated A375c.XI.
FACS analysis for H-2Kb expression and recovery at the cell
surface
To study the kinetics of endogenous surface Kb recovery cells
were treated with ice-cold citric acid buffer (0.13 M citric acid,
0.061 M Na2HPO4, 0.15 M NaCl [pH 3]) at 1 × 10
7 cells per
milliliter for 120 s, washed three times with PBS, and resus-
pended in culture medium. At the indicated time point, a cell
aliquot (generally 1.5 × 106 cells) was removed and stained with
anti-mouse 25-D1.16 antibody, used for the detection of spe-
cific MHC-I/peptide-complexes (H-2Kb+SIINFEKL) at the cell
surface. All flow cytometry experiments were conducted using
the BD LSRII flow cytometer (BD Biosciences) and data were
analyzed with the FlowJow software (V10).
In vitro peptide degradation
Reconstitution of REG-20S complexes and the degradation of
short fluorogenic substrates, the MP-45 and the KH-52 poly-
peptides (containing the SIINFEKL epitope in their middle) or
the MP-46 and the KH-53 polypeptides (containing the MBP
epitope in their middle), were performed according to pre-
viously described methods.35–37 Briefly, PSME3- and REGα/β-
20S proteasomes were reconstituted by preincubating human
20S constitutive or immuno particles (BostonBiochem, USA)
with a 6-fold molar excess of PSME3 (BostonBiochem, USA)
or REGαβ36 at 37°C for 30 min in 20 mM HEPES, pH 7.6, and
2 mM NaCl and were immediately used for degradation experi-
ments. For kinetic analysis and to generate peptide products for
MS/MS studies, all polypeptides (50 µM) were incubated with
20S, PSME3-20S or REGα/β-20S (20 nM) for 8 h at 37°C in
20 mM HEPES, pH 7.6, 2 mM NaCl. To assay the peptides
generated during protein degradation, we measured the appear-
ance of new amino groups using fluorescamine as previously
described.37 In brief, at the end of the incubation, the peptide
products were separated from undegraded polypeptides by
ultrafiltration through a membrane with a 3-kDa cutoff
(Nanosep, Pall, USA), and these samples were assessed with
fluorescamine (Sigma) and used for MS/MS analysis.
Liquid chromatography–tandem MS (LC–MS/MS) analysis
Five-microliter samples from the 20S -/+ PSME3 8 hour degra-
dation experiments containing approximately 130 pmol NH2
/µl were loaded onto StageTipsµC18;38,39 peptides were eluted
in 40 μl of 80% acetonitrile in 0.1% formic acid. The acetoni-
trile was allowed to evaporate in a Speed-Vac, and then the
samples were resuspended in 6 µl of eluent A (see the composi-
tion below) for nLC-MS/MS analysis. Two microliters of each
sample was injected as technical replicates into a nLC–ESI–
MS/MS quadrupole Orbitrap QExactive-HF mass spectro-
meter (Thermo Fisher Scientific). Peptide separation was
achieved using a linear gradient from 95% solvent A (2%
ACN, 0.1% formic acid) to 50% solvent B (80% acetonitrile,
0.1% formic acid) for 23 min and from 60 to 100% solvent B for
2 min at a constant flow rate of 0.25 µl/min on a UHPLC Easy-
nLC 1000 (Thermo Scientific) connected to a 25-cm fused-
silica emitter with an inner diameter of 75 µm (New
Objective, Inc. Woburn, MA, USA), packed in-house with
ReproSil-Pur C18-AQ 1.9-µm beads (Dr. Maisch Gmbh,
Ammerbuch, Germany) using a high-pressure bomb loader
(Proxeon, Odense, Denmark). MS data were acquired using
a data-dependent top-15 method for HCD fragmentation.
Survey full-scan MS spectra (300–1750 Th) were acquired in
the Orbitrap at a resolution of 60,000, an AGC target of 1e6, and
an IT of 120 ms. For the HCD spectra, the resolution was set to
15,000 at m/z 200, with an AGC target of 1e5, an IT of 120 ms,
an NCE of 28% and an isolation width of 3.0 m/z.
Data processing and analysis
For quantitative proteomic analysis, raw data were processed
with MaxQuant (ver. 1.5.2.8) and searched against a database
containing the sequence of the KH-52 intron SIINFEKL+ con-
taminant fasta included in MaxQuant. No enzyme specificity
was selected, and there were no differences between I and L. The
mass deviation for MS-MS peaks was set at 20 ppm, and the
peptide false discovery rate (FDR) was set at 0.01; the minimal
length required for a peptide identification was eight amino
acids. The list of identified peptides was filtered to eliminate
contaminants. Statistical analyses were performed with Perseus
(ver. 1.5.1.6) considering the peptide intensity; normalization
based on the Z-score and imputation was applied. Significant
peptides were determined with a t-test, Benjamini Hochberg
correction and FDR<0.05 (more stringent assignments), or
a t-test with a p-value of 0.05 (less stringent assignments).
Only significant peptides were used for supervised hierarchical
clustering analysis. MS data as raw files, peptides identified with
relative intensities, peptide score, PEP, etc. and search para-
meters have been loaded into Peptide Atlas repository (ftp://
PASS01235:LR6858ie@ftp.peptideatlas.org/).
Tumor challenge in-vivo
C57Bl/6J female mice were obtained fromHarlan Laboratories.
NU/NU nude mice were obtained from Charles River. 7-week-
old mice were injected subcutaneously into the right flank with
1 × 105 MCA205 wild type (WT) cells or 1 × 105 Cas9-PSME3
MCA205 clones. Area of the tumor was recorded every 3 to
4 days until ethical limit points are reached. All animal experi-
ments were authorized and validated by the ethics committee n
°26 of University Paris-Saclay in compliance with the European
directive 2010/63 UE and its transposition into French law.
Results
The expression of PSME3 is inversely correlated with the
level of antigen presentation in multiple cancer cell lines
A series of studies have reported the overexpression of PSME3
in different cancer types.40–43 To clarify the specific role of
PSME3 in MHC-I antigen presentation, we selected different
cancer cell lines and examined PSME3 mRNA and protein
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expression levels. First, we analyzed PSME3 mRNA levels by
real-time qRT-PCR in three human melanoma cell lines (A375,
WM3526 and WM3682), one human lung cancer cell line
(A549) and two colon cancer cell lines (HT29 and T84), and
we observed that PSME3 was notably upregulated in each cell
line compared to the control normal lung fibroblast cell line
MRC5 (Figure 1(a)). Next, we measured PSME3 protein
expression and observed that it was overexpressed in all cancer
cell lines compared with MRC5 normal cells, although levels of
PSME3 overexpression varied between the different cell lines
analyzed. Indeed, PSME3 was highly overexpressed in mela-
noma and colon cancer cell lines, expressed at low levels in the
lung cancer cell line A549, and demonstrated very low expres-
sion in the normal cell line (Figure 1(b)). Furthermore, we
assessed the cellular distribution of PSME3 in these cancer
cell lines. Figure 1(c) shows that endogenous PSME3 is loca-
lized in the nucleus of all cell lines analyzed independently of
its expression levels.
To evaluate whether the observed differences in PSME3
expressions in cancer and normal cell lines contribute to
changes in antigen production and presentation, we examined
the presentation of PTP-derived antigens at the cell surface of
these cell lines. To achieve this goal, we expressed the mouse
MHC-I H-2Kb molecule and the Glob-intron-SL8 constructs in
these human cell lines to examine the production of specific
SL8-comprising PTPs as described previously.6,7 Using a -
SIINFEKL:Kb (B3Z) T cell hybridoma32 that specifically detects
the SL8 epitope presented on Kb molecules, we first found that
the antigen presentation was lower in all cancer cell lines tested
than in the normal MRC5 cell line (Figure 1(d), left panel and
Fig. S1D). Interestingly, we observed a complete inverse corre-
lation between PTP-derived-SL8 presentation and PSME3
expression in all cell lines tested. This result suggested that
PSME3 overexpression negatively affected PTP-derived anti-
gen presentation (compare Figure 1(b,d)). Crucially, this result
was not merely due to differences in the cellular level of the β-
globin construct, which in fact were higher in tumor cell lines
overexpressing PSME3 (Fig. S1A). Moreover, FACS analysis
showed that the overall H-2Kb expression differs among the
cancer cell lines tested but the variations observed do not
correlate with the expression of SL8 as determined with the
B3Z assay. In fact, we observed that MHC-I molecules were
Figure 1. Inverse correlation between the expression of PSME3 and antigen presentation in multiple cancer cell lines. (a) PSME3 mRNA levels were analyzed by RT-qPCR
in different cell lines and normalized to β-actin mRNA levels. The MRC5 cell line was used as a reference. Experiments were performed in triplicate. Data are expressed as
the mean ± SEM from three technical replicates. (b) Western blot analysis and quantification (relative to the housekeeping protein β-actin) of PSME3 expression. Protein
levels are indicated below each gel. (c) PSME3 protein localization was determined by immunofluorescence in several tumor cell lines and in the MRC5 normal cell line.
PSME3 was stained with Alexa Fluor 488, and nuclei were counterstained with DAPI. Cells were analyzed by confocal microscopy. As expected, the regulator PSME3 was
localized in the nucleus in all tested cell lines. (d, e) All cell types were transfected in vitro with Glob-intron-SL8 (d, left panel) or Glob-intron-MBP(79–87) (d, right panel),
β-Glob-exon-SL8 (e, left panel) and OVA cDNA (e, right panel) expression constructs. The cells were incubated with the SL8-specific CD8+T cell hybridoma (B3Z) for 16h.
The data show the average of at least three independent experiments ± SD minus the values from mock-transfected cells. Free SL8 peptides were added to the cells to
ensure that the T cell assays were performed under non-saturation conditions and that the expression of MHC-I molecules was not affected.
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more abundant at the cell surface of tumor cell lines over-
expressing PSME3 and exhibiting a decrease in PTP-
dependent antigen presentation (Fig. S1B).
In order to rule out the possibility that the negative role of
PSME3 on PTP dependent antigen presentation could be
restricted to the SL8 epitope or the Kb molecule, we determined
whether also the presentation of the MBP(79–87) epitope,
which is derived from the Myelin Basic Protein (MBP) and is
presented on H-2Kk molecules was affected by the overexpres-
sion of PSME3 in different cancer cell lines. Using the specific
MBP CD8+T cell hybridoma33 we could obtain results similar
to those previously observed with the PTP-derived SL8, that is
to say a complete inverse correlation between PTP-derived
MBP presentation and PSME3 expression in all cancer cell
lines tested (Figure 1(d), right panel). All together, these results
indicate: i) a negative role of PSME3 in the MHC-I antigen
presentation pathway since antigen presentation was reduced
in all cancer lines overexpressing the PSME3 regulator while
the β-globin protein and the MHC-I molecules were more
abundant in the same cell lines and ii) that the inverse correla-
tion between PSME3 expression and antigen presentation is
not restricted to a specific epitope or MHC-I molecule.
We then wanted to determine whether the previously
observed differences in SL8 antigen presentation were
restricted to intron-derived tumor-associated antigens or if
they were also observed with an exon-derived tumor-
associated antigen. To this purpose, we analyzed cells expres-
sing mouse MHC-I Kb molecules and the Glob-exon-SL8 con-
struct or the ovalbumin cDNA, in which the SL8 epitope is
found in its correct setting. As shown in Figure 1(e), antigen
presentation showed an inverse correlation with PSME3
expression in all cell lines tested, independently of the position
of the antigenic epitope in the exon sequence (left panel) or in
cDNA constructs (right panel) even if with the cDNA con-
struct the effect of PSME3 on antigen presentation was weaker.
Furthermore, we expressed in the different human cell lines
the mouse MHC-I H-2Kb molecule and the SL8-minigene
construct, which contains only the presented 8-amino-acid
sequence of SL8 and does not require an additional processing
step to be exported by the TAP system in to the ER and to be
loaded on the MHC class I molecules.44 Importantly, we
observed that differences in PSME3 expression did not corre-
late with SL8 antigen presentation (Fig. S1C). Hence, the effects
of PSME3 on MHC-I antigen presentation only occurs with
longer polypeptides containing the presented MHC-I antigenic
peptides, indicating that PSME3 directly acts on epitopes pro-
cessing and not on subsequent steps of class-I presentation.
All together these results clearly support the hypothesis that
the proteasome regulator PSME3 is involved in the inhibition
of the MHC-I presentation of antigens from exon- as well as
intron-derived PTPs, a mechanism that may allow tumor cells
to avoid immune responses against conventional and uncon-
ventional epitopes.
Exogenous overexpression of PSME3 decreases
MHC-I antigen presentation
In the rest of our study we decide to use the Glob-intron-SL8
construct since, due to its nuclear localization it is the most
appropriate tool to investigate the role of a nuclear proteasomal
regulator on PTP-dependent antigen presentation. To study
the specific effects of PSME3 on PTP-dependent MHC-I anti-
gen presentation, MRC5 lung fibroblast cells and A549 lung
cancer cells which express PSME3 at very low levels, (see
Figure 1(a,b)), were therefore co-transfected with the mouse
MHC-I Kb molecule, the Glob-intron-SL8 and the exogenous
Flag-PSME3 constructs. Using Western blotting (Figure 2(a)),
immunofluorescence (Figure 2(b)) or qRT-PCR (Fig. S2), we
monitored the expression of the exogenous PSME3 construct
and compared it to the expression of endogenous PSME3.
Notably, the overexpressed exogenous PSME3 showed the
same expression pattern and localization as the endogenous
PSME3. Next, we examined the antigen presentation of the SL8
epitope in these cell lines. The introduction of increasing
amounts of PSME3 in both A549 and MRC5 cell lines, which
express fixed amounts of the Glob-intron-SL8 construct and
MHC-I Kb molecules, resulted in a dose-dependent decrease in
the activation of the B3Z hybridoma (Figure 2(c)). This obser-
vation supports the hypothesis that the overexpression of
PSME3 has a clear-cut negative effect on PTP-dependent anti-
gen presentation.
As mentioned earlier, PSME3 is not the sole regulator of the
proteasomal pathway; 20S proteasome also binds to the REGα/
β regulator, which has been shown to be implicated in the
accurate processing of MHC-I antigenic epitopes.14 To inves-
tigate in more detail at which exact level of the proteasomal
pathway PSME3 contributes to PTP-dependent antigen pre-
sentation regulation, we determined whether the overexpres-
sion of PSME3 influenced the expression of endogenous REGα.
Figure 2(d) shows that increasing the amount of exogenous
PSME3 did not affect the expression of REGα. This result
therefore demonstrates that the decrease in PTP-dependent
antigen presentation caused by PSME3 in different cancer cell
lines is not due to a decrease in the expression of the regulator
REGα but more likely it results from a direct effect on the 20S
proteasome. In fact, the presentation of antigenic peptides
depends on proteolytic processing by proteasome complexes
that are known to possess the capacity to process and destroy
epitopes.45 To ensure that differences in the production of SL8
peptides by the proteasome can be at least partially attributable
to the overexpression of PSME3, we treated MRC5 cells expres-
sing increasing amounts of PSME3 and a fixed amount of
Glob-intron-SL8 and MHC-I Kb molecules with the 20S pro-
teasome-specific inhibitor epoxomicin and examined SL8 pre-
sentation. Importantly, to perform these experiments, we
utilized a dose of inhibitor (i.e. 300 nM) that does not com-
pletely annihilate all three peptidase activities of proteasome46
as demonstrated by the only partial reduction of SIINFEKL
presentation in Figure 2(e) and by the partial stabilization of
p21 levels in Figure 2(f). Interestingly, while non-inhibited cells
displayed a decrease in antigen presentation with PSME3 over-
expression, a partial increase in MHC-I antigen presentation
was observed when cells were treated with epoxomicin
(Figure 2(e)). Although we cannot exclude that PSME3 may
also exert some positive proteasome-independent activity on
antigen presentation, this observation supports the idea that
PSME3 exerts a direct activity on 20S core particle, consisting
in a fine tuning of the balance between proteolytic activities
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that generate and destroy epitopes (and that are not equally
sensitive to epoxomicin), with the final result that the genera-
tion of SIINFEKL is increased by this partially inhibited pro-
teasome. Accordingly, previous reports clearly demonstrated
that proteasome inhibitors are able to block generation of some
antigenic peptides and enhance production of others.47
Moreover, as a control for the efficacy of the proteasomal
partial inhibition under the condition used in the treated cell
lines, we examined p21 protein levels, which has been reported
to be regulated specifically by the PSME3-20S proteasome
complex in an ubiquitin and ATP-independent process.18 As
shown in Figure 2(F), p21 protein levels increased following
18 h of epoxomicin treatment, but this increase was still
reduced in cells overexpressing the exogenous PSME3 regula-
tor, which showed the presence of residual proteasome activity.
Therefore, all these results confirm that the overexpression
of PSME3 does not induce (i) a decrease in MHC-I expression
or export or (ii) a decrease in the expression of the other
members of the REG family, but does directly affect proteaso-
mal proteolytic activities.
Knockdown and knockout of the regulator PSME3
promote antigen presentation
Considering our finding showing that endogenous overexpres-
sion of the PSME3 regulator negatively affects MHC-I antigen
presentation in cancer cells, we speculated whether PSME3
knockdown might restore PTP-dependent antigen presenta-
tion. To test this hypothesis, we silenced PSME3 by transient
siRNA treatment in human melanoma and colon cancer cell
lines. As expected, PSME3 knockdown (Figure 3(a)) enhanced
p21 protein levels in all cancer cell lines compared to scrambled
siRNA (Figure 3(b)). More importantly in terms of PTP-
dependent antigen presentation, we observed a close correla-
tion between PSME3 knockdown and the increase of the SL8
epitope at the cell surface (Figure 3(c)).
The expression of PSME3 is controlled by several mechan-
isms inside the cell. miRNA-7, which has been reported as
a tumor suppressor48,49 and is downregulated50,51 in several
human cancers, also negatively controls the expression of the
regulator PSME3 in lung cancer.52 The A375 melanoma cancer
Figure 2. Exogenous PSME3 overexpression decreases antigen presentation. (a) MRC5 and A549 were transfected with a construct expressing PSME3 WT from 0.0625 to
0.5 µg or a corresponding empty construct for 48 h. PSME3 protein levels were examined by Western blotting using β-actin as a loading control. Protein levels are
indicated below each gel. (b) MRC5 and A549 were transfected with a construct expressing Flag-PSME3 WT (0.25 µg). The Flag tag was stained with Alexa Fluor 488, and
the nuclei were stained with DAPI. Cells were analyzed by confocal microscopy. As expected, exogenous transfected PSME3 WT localized in the nuclei. (c) MRC5 cells (left
panel) and A549 cells (right panel). The cells were incubated with the SL8-specific CD8+T cell hybridoma (B3Z) for 16 h. The data show the average of at least three
independent experiments ± SD minus the values from mock-transfected cells. All cells were transfected with increasing amounts (from 0 to 0.5 μg) of Glob-intron-SL8
construct with a final total concentration of 1 µg of plasmids in each cell lines. (d) MRC5 cells were transfected with a PSME3 WT construct for 48 h. The increase in
PSME3 protein expression had no effect on the expression of REGα protein. (e) MRC5 cells were transfected with increasing amounts (from 0 to 0.5 μg) of Flag-PSME3
construct for 48 h. At 36 h post-transfection, the cells were then treated overnight with epoxomicin (300 nM). Next, the cells were incubated with the B3Z T cell
hybridoma for 16 h. The data show the average of at least three independent experiments ± SD. *** p <.001, * p <.05 (unpaired t-test). (f) Western blot analysis and
quantification (relative to the housekeeping protein β-actin) of p21 expression in MRC5 cells treated overnight with epoxomicin at 300 nM. Protein levels are indicated
below each gel. As expected, p21 protein levels increased after 12 h of epoxomicin treatment, even though the treated cells overexpressed the exogenous regulator
PSME3.
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cell line, which in our hands expressed the highest levels of
PSME3, was therefore transfected with increasing amounts of
miRNA-7. Of great interest, we observed that miRNA-7 inhib-
ited PSME3 expression (Fig. S3A) and led to an increase in
PTP-SL8-dependent antigen presentation (Fig. S3B). In addi-
tion, treatment of cancer cells with the chemotherapeutic
molecule cisplatin has been shown to induce a decrease in
mRNA and protein levels of PSME353 (and Fig. S3C).
Accordingly, treatment of A375 cells with cisplatin restores
the expression of PTP-dependent antigens at the cell surface
(Fig. S3D). All together, these results support the idea that
PSME3 downregulation restores PTP-derived antigen presen-
tation and indicate a possible chemotherapeutic approach to
achieve this goal.
To clarify in more detail the functional importance of PSME3
in cancer immune escape, we used the CRISPR/Cas9 system to
create a melanoma Cas9-A375 PSME3-knockout cell line
(A375cXI). The heterozygous knockout A375cXI was confirmed
by Sanger sequencing, qRT-PCR andWestern blot analysis. The
A375cXI cell line did not express PSME3 mRNA (Figure 3(d))
or its corresponding protein (Figure 3(e)). As a control for the
loss of PSME3 expression, the p21 protein accumulates in this
cell line as in cells that were knocked down with specific PSME3
siRNAs (Figure 3(e)). CruciallyA375cXI cells showed increased
PTP-dependent antigen presentation compared to A375WT or
A375 cell lines that are only knocked down for PSME3 expres-
sion (figure 3(f)). Moreover, the level of SL8 antigen presenta-
tion in these cell lines was even higher than the control MRC5
line which weakly expresses PSME3 (figure 3(f)). Differences in
PSME3 levels are likely to account for this result, since both the
tested cell lines (A375cXI and A375WT) expressed equal
amounts of exogenous Glob-intron-SL8 protein (Fig. S3E, left
panel) as well as equal amounts of the mouse MHC class
I molecule at their cell surface (Fig. S3E, right panel).
In order to rule out the possibility that the negative role of
PSME3 on PTP dependent antigen presentation could be
restricted to the SL8 epitope or the Kb molecule, we also
determined whether the presentation of an endogenous
Figure 3. Knockdown and knockout of the expression of the regulator PSME3 promotes antigen presentation. The A375, WM3526, WM3682, HT29 and T84 cell lines
were transfected with siRNA specific for PSME3 (50 and 100 nM) or siRNA negative control (0) for 48 h and then analyzed by RT-qPCR (a), Western blotting (b) and a T cell
assay (c). (a) Experiments were performed in triplicate. Data are expressed as the mean ± SEM of three technical replicates. (b) Western blotting was performed to
analyze and quantify PSME3 and p21 expression, and β-actin was used as a reference protein. The relative protein level is indicated below each gel. (c) Cell lines were
transfected with the Glob-intron-SL8 construct (0.5 μg) and treated with different concentrations of siRNA specific for PSME3 (0, 50 and 100 nM). After 48 h, the different
cell lines were incubated with the B3Z T cell hybridoma for 16 h. The data show the average of at least three independent experiments ± SD minus the values from
mock-transfected cells. (d) qPCR analysis of A375 cells transfected with siRNA specific for PSME3 (50 and 100 nM) was performed. The inhibition of PSME3 mRNA levels
was quantified and normalized to β-actin mRNA levels. Experiments were performed in triplicate. Data are expressed as the mean ± SEM from three technical replicates.
(e) Western blot analysis and quantification (relative to the housekeeping protein β-actin) of PSME3 and p21 expression. Protein levels are indicated below each gel. (f)
The A375cXI and A375 cell lines were both transfected with the Glob-intron-SL8 construct (0.5 μg) for 48 h, and PSME3-siRNA (50 or 100 nM) was only added to A375
cells. The cells were incubated with the B3Z T cell hybridoma for 16 h. The data show the average of at least three independent experiments ± SD minus the values from
mock-transfected cells. *** p <.001, ** p <.01 (unpaired t-test). (g) The A375, A375cXI, WM3526 and WM3682 cell lines were co-transfected with the Glob-intron-SL8
(0.5 μg) and the H2-Kd (0.5 μg) constructs for 48 h. The different cell types were then incubated with the Busa14 T cell hybridoma for 16 h. The data show the average of
at least three independent experiments ± SDminus the values frommock-transfected cells. ** p <.01 (unpaired t-test). Note that panel C refers to the experiment shown
in panels A and B, while panel F refers to the experiment of panel E. Differences in the magnitude of B3Z activation correlate with the extent of PSME3 reduction
obtained by siRNA in the different experiments.
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epitope from the melanoma cell line, the gp100(25-33) epitope,
which is derived from the Pmel17/gp100 protein, was affected
by the overexpression of PSME3 in the different melanoma
cancer cell lines tested in Figure 1. Using the specific Busa14
CD8+ T cell hybridoma that has been shown to specifically
recognize the gp100(25-33) epitope on H2-Kd molecules,33 we
observed that the presentation of the endogenous epitope is
enhanced at the surface of A375cXI cells compared to its
parental cell line or other melanoma cell lines where PSME3
is overexpressed (Figure 3(g)). This result demonstrates that
PSME3 also has the capacity to negatively regulate the presen-
tation of an endogenous MHC class I antigen.
All together these results clearly confirm that there is an
inverse correlation between the expression of PSME3 and PTP-
dependent antigen presentation in cancer cell lines. This effect
is likely due to a close control of the proteasomal degradation
pathway and not to an overall effect of PSME3 on MHC-I
molecule expression and export to the cell surface.
PSME3 regulates the nuclear proteasomal pathway
In our previous studies, we demonstrated that PTPs are pro-
duced by a translation event that is distinct from canonical
translation and occurs prior to mRNA splicing, supporting the
idea that PTPs are generated by a nuclear translation event.
Furthermore, we have also reported that treatment with the
proteasome inhibitor epoxomicin increases the amount of
PTPs within the nuclear compartment, indicating that the
nuclear proteasome may be involved in the processing and/or
degradation of PTP-antigenic epitopes.7 Based on these studies
and all our results so far, we next sought to understand how
PSME3 contributes to the specific inhibition of PTP-dependent
cancer immune responses and in which cell compartment this
inhibition occurs. Antigenic epitopes derived from PTP pro-
cessing are generated either by a cytosolic or nuclear proteaso-
mal complex, in which the REG family plays an essential role.
As proteasomal regulator, PSME3 has to bind to the 20S
proteasome to control protein or polypeptide degradation
and this interaction should occur in the nucleus. A PSME3
gene sequence mutation that leads to the replacement of Asn
151 by Tyr (N151Y) has been reported to impair the ability of
the regulator to activate the trypsin-like activity of the 20S
proteasome.54 A375cXI cells were transfected with increasing
amounts of Flag-PSME3 WT or mutated Flag-PSME3-N151Y.
First, we showed by western-blotting that the mutated regula-
tor was no longer able to degrade the p21 protein likely as
a direct consequence of its inability to activate the trypsin-like
activity of the 20S proteasome. Moreover, the expression of the
other members of the REG family was not impacted under all
the experimental conditions used (Figure 4(a)). More impor-
tantly, PSME3-N151Y inhibited SL8 antigen production and
presentation at the cell surface from Glob-intron-SL8 less
efficiently than PSME3-WT (Figure 4(b)). This inhibition of
SL8 presentation again was not attributable to a decrease in
expression of the other REG family members shown to be
involved in antigen presentation. Two explanations are there-
fore consistent with this result: i) exogenous mutated PSME3-
N151Y may no longer be localized in the nucleus; or ii) exo-
genous mutated PSME3-N151Y may have lost its capacity to
bind to the 20S proteasome and, therefore, contrary to PSME3-
WT it is no longer able to inhibit proteasome activity. To
discriminate between these two alternative hypotheses, we
first examined the distribution of the mutated PSME3-N151Y
as well as its capacity to bind to the 20S proteasome in cellulo.
As shown in Figure 4(c) and Fig. S4A, the mutated and WT
exogenous PSME3 regulators are both localized in the nucleus.
Since we did not observe any differences in the localization that
could explain the differences in the production of MHC class
I epitopes between the cell lines expressing the mutated or the
WT regulators, we determined whether mutated Flag-PSME3-
N151Y retained the capacity to bind to the nuclear 20S protea-
some in cellulo. To achieve this goal, we used proximal ligation
assay (PLA)-labeled secondary antibodies, which allow the
detection of two primary antibodies in close proximity. Using
a combination of PLA-labeled anti-Flag and anti-proteasomal
α4 antibodies, we observed a specific signal in the nuclear
compartments of cells expressing the mutated and PSME3-
WT constructs, revealing the co-localization of both form of
PSME3 with the 20S proteasome (Figure 4(d) and Fig. S4B).
Furthermore, as a control, anti-Flag alone under these condi-
tions produced no PLA reaction, and no positive signals were
detected in non-transfected cells (Figure 4(d), top panel). We
confirmed further the interaction between PSME3 WT and
mutated PSME3-N151Y with the 20S core proteasome by
coimmunoprecipitation using an antibody directed against
the PSME3 regulator (Figure 4(e)). Localization and capacity
to bind to the 20S core were equivalent between exogenous
PSME3WT and mutated PSME3-N151Y, again demonstrating
that the PSME3-20S proteasome complex is involved in the
processing/degradation of PTP-derived antigenic peptides.
To further define the compartment hosting PSME3-dependent
PTP degradation, we generated an exogenous Flag-PSME3 con-
struct that did not contain a nuclear localization signal (NLS).
Unlike PSME3-WT, PSME3-ΔNLS was expressed throughout the
cell and was not anymore confined to the nucleus (Figure 4(c) and
Fig. S4A). The combination of PLA-labeled anti-Flag and anti-
proteasomal α4 antibodies produced a specific signal in the cyto-
plasmic compartments of cells expressing the PSME3-ΔNLS and
PSME3WT constructs. We also observed staining corresponding
to an interaction between PSME3-ΔNLS and the 20S core in the
nucleus. This result indicates that PSME3-ΔNLS, which was loca-
lized throughout the cell, retained the capacity to bind to the 20S
proteasome in both the cytoplasm and the nucleus (Figure 4(d),
left bottom panel and Fig. S4B).We also confirmed the interaction
between PSME3WT and PSME3-ΔNLSwith the 20S core protea-
some by coimmunoprecipitation using an antibody directed
against the PSME3 regulator (Figure 4(e)). Moreover, Cas9-
A375 PSME3-knockout cell line (A375cXI) cells transfected with
PSME3-ΔNLS slightly prevented nuclear 20S proteasome degra-
dation of the p21 protein in a PSME3-dependent manner com-
pared to cells transfected with PSME3 WT (Figure 4(f)). This
result suggests that the low levels of PSME3-ΔNLS in the nucleus
retained the capacity to partially activate the nuclear 20S protea-
some and, furthermore, demonstrate that the degradation of the
p21 protein is a nuclear and not a cytoplasmic event (Figure 4(F)).
In parallel, when we examined the effect of the partial relocaliza-
tion of PSME3-ΔNLS in the cytoplasm on the antigenic presenta-
tion pathway, we observed an increase in PTP-dependent antigen
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presentation compared to the loss of antigen presentation in cells
expressing exogenous nuclear PSME3 WT (Figure 4(g)).
All these results hence demonstrate that PSME3 is involved
in PTP-dependent antigen presentation by binding to the
nuclear 20S proteasome.
PSME3 promotes the degradation of MHC class I
PTP-derived antigenic epitopes
The above results raised at least two alternative hypothesis
regarding the role of PSME3 in the PTP-dependent proteaso-
mal degradation pathway: i) PSME3 may inhibit 20S proteaso-
mal peptidase activities responsible for producing antigenic
peptides with the correct characteristics (i.e. length and anchor
residues) to serve in MHC-I pathway, with a consequent
decrease in production of PTP-dependent epitopes; or ii)
PSME3 may stimulate specific 20S proteasomal activities that
cause further degradation of the correct size MHC-I antigenic
epitopes. Recently, we showed that inhibition of the proteaso-
mal pathway with epoxomicin leads to increased amounts of
unprocessed PTPs in cells and promotes the cross-presentation
of longer polypeptides compared with untreated cells.8 To test
the first hypothesis, we transfected different cancer cell lines,
normal MRC5 fibroblasts and the Cas9-A375 PSME3-
knockout cell line with the Glob-intron-SL8 construct and
incubated them with mouse BMDCs for 24 h. We observed
a reduction in B3Z activation when the tumor cell lines were
incubated with BMDCs compared to normal MRC5 cells while
A3cXI showed enhanced antigen presentation (Figure 5(a)).
The decrease in cross-presentation in the different cell lines
Figure 4. PSME3 regulates the nuclear proteasomal pathway. (a) Western blotting was performed to analyze and quantify PSME3, REGα and p21 protein expression in
A375cXI cells (relative to the housekeeping protein β-actin). The cells were transfected with a construct expressing PSME3 WT or the mutated PSME3 N151Y at different
concentrations or with a corresponding empty construct for 48 h. Protein levels are indicated below each gel. (b) A375cXI cells transiently expressing the mouse H-2Kb
molecules and the intron-derived SL8 epitope. The same cells were co-transfected with increasing amounts (from 0 to 0.5 μg) of constructs expressing Flag-PSME3 WT
or the mutated Flag-PSME3-N151Y at different concentrations and then incubated with the B3Z T cell hybridoma for 16 h. Data are the average of at least three
independent experiments ± SD minus the values from mock-transfected cells. (c) A375cXI cells were transfected with a construct expressing a Flag-PSME3 WT or a Flag-
PSME3 N151Y or a Flag-PSME3-ΔNLS. The Flag tag was stained with Alexa Fluor 488, and the nuclei were stained with DAPI. Cells were analyzed by confocal microscopy.
As expected, the exogenous PSME3 WT and PSME3-N151Y proteins were localized in the nuclei, when PSME3ΔNLS was localized in the nucleus and in the cytoplasm. (d)
The interactions of the 20S proteasome with the exogenous Flag-PSME3 WT or a Flag-PSME3-N151Y or a Flag-PSME3-ΔNLS constructs were analyzed using DuoLink. PLA
was performed using an antibody against the Flag tag and α4 subunit – of the 20S proteasome. Staining was analyzed by confocal microscopy. (e) Immunoprecipitation
was performed using the PSME3 antibody, and Western blotting was carried out using an antibody against the 20S α6 subunit. For that purpose the A375cXI CRISPR cell
line was transfected with the different Flag-PSME3 constructs and a comparison was made with the endogenous PSME3 in the A375 for the capacity of the Flag
construct to bind to the 20S core compare to the endogenous PSME3. This experiment confirmed the interaction of the 20S proteasome and exogenous PSME3 WT or
PSME3-N151Y. (f) Western blot analysis and quantification (relative to the housekeeping protein β-actin) of PSME3, REGα and p21 protein levels in A375c.XI cells
transfected with a construct expressing PSME3-WT or PSME3-ΔNLS at different concentrations or with a corresponding empty construct for 48 h. Protein levels are
indicated below each gel. (g) A375cXI cells transiently expressing the mouse H-2Kb molecules and intron-derived SL8 epitope. The same cells were co-transfected with
increasing amounts (from 0 to 0.5 μg) of constructs expressing Flag-PSME3 WT or the mutated Flag- PSME3-ΔNLS at different concentrations and were incubated with
the B3Z T cell hybridoma for 16 h. Data are the average of at least three independent experiments ± SD minus the values from mock-transfected cells.
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overexpressing PSME3 suggested that PSME3 did not inhibit
PTP processing since the accumulation of unprocessed poly-
peptides would have been a source of material for the exogen-
ous MHC-I pathway. To confirm that PSME3 did not inhibit
the capacity of 20S proteasome to hydrolyze long polypeptides,
we assessed the effects of this regulator on the 20S core particle
cleaving properties by using an in-vitro degradation assay. For
that purpose, a 45-mer (MP-45) and a 52-mer (KH-52) pre-
cursor peptides containing the SIINFEKL epitope as well as
a 46-mer (MP-46) and a 53-mer (KH-53) precursor peptides
containing the MBP(79–87) epitope were synthesized (Fig.
S5A). The 45-mer and the 46-mer precursor peptides corre-
spond to the amino acid sequence of the β-globin exon region
in which the SL8 or theMBP(79–87) epitopes are introduced in
the construct used in Figure 1(e). The 52-mer and the 53-mer
precursor peptides correspond to the amino acid sequence of
the β-globin intron region in which the SL8 and the MBP
(79–87) epitope are introduced in the same construct used in
Figure 1(d). Importantly, preliminary studies demonstrated
that the commercial enzymes used in these experiments were
active and free of contaminant proteases, as shown by the
ability of epoxomicin to completely inhibit the chymotrypsin-
and trypsin-like activities of these preparations (Table S1).
Moreover, although it is well known that the free 20S particle
is a relatively inactive protease, presumably because the
N-terminal tails of its α subunits obstruct the two opposite
axial pores through which substrates access the internal cata-
lytic lumen,55 the latency of unliganded 20S proteasome is not
absolute. Indeed, even in the absence of artificial treatments
that are known to activate it,56 the 20S core particle degrades
proteins at detectable and reproducible rates, probably by
a mechanism involving transient and/or only partial channel
opening.57,58 Furthermore, in line with these in vitro findings,
several studies indicate that a significant fraction of cellular
proteins are also degraded in vivo by 20S proteasomes in an
ubiquitin- and ATP-independent process.59–61 Hence, KH-52
and KH-53 were incubated in vitro with human constitutive
20S proteasome at 37°C for several hours, and the rates of
Figure 5. PSME3 promotes the degradation of MHC-I PTP-derived antigenic epitopes. (a) A375, WM3526, WM3682, HT29, T84, A549, MRC5 and A375cXI cell lines
expressing the Glob-intron-SL8 construct (0.5 μg) were cultured with BMDCs for 24 h. The BMDCs were then co-cultured with the SL8-specific CD8+T cell hybridoma
(B3Z) for 16 h, and T cell activation was estimated by measuring β-galactosidase levels. The data show the average of at least three independent experiments ± SD
minus the values from mock-transfected cells. *** p <.001, ** p <.01, * p <.05 (unpaired t-test). Hydrolysis rates of KH-52 and KH-53 (b) and MP-45 and MP-46 (c)
peptides. Precursor substrates were incubated with human 20S constitutive proteasomes (h20Sc) alone or activated by PSME3 or REGα/β, and the amino groups
released were measured with fluorescamine at the indicated time points. Data are representative of three independent experiments. (d) Heatmap comparison of the
abundance of significant peptides generated after 8 hours from proteasomal degradation of KH-52 precursor peptide in the h20Sc (biological and technical replicates of
samples designated A and C, respectively) and PSME3-h20Sc (biological and technical replicates of samples designated B and D, respectively) samples. Samples were
analyzed by nLC-MS/MS and processed by MaxQuant against the database KH-52 Intron SIINKEL + contaminant sequences. Differences and similarities in peptide
intensities (normalized to the Z-score) are shown; green indicates decreased levels, and red indicates increased levels. Data were obtained from supervised hierarchical
clustering analysis by applying a t-test, the Benjamini Hochberg correction and a p-value of 0.05. (e) Box plot of SIINFKEL peptide intensity calculated by MaxQuant in
the h20Sc (in green) and PSME3-h20Sc (in blue) samples. (f) Cross presentation assay of peptide products generated during hydrolysis by 20S proteasome of KH-52
peptide precursor in the presence or absence of PSME3. *** p <.001 (unpaired t-test).
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peptide bond hydrolysis were assessed by measuring the gen-
eration of new amino groups with fluorescamine.37 Under
these conditions, KH-52 and KH-53 were clearly degraded by
h20Sc at linear rates over the entire time course of incubation
(Figure 5(b)). Moreover, the rates of peptide bond hydrolysis
were not appreciably enhanced in the presence of PSME3 and
appeared to be only slightly lower than the rates measured
when the proteasome associated with REGα/β (Figure 5(b),
compare blue and red curves, left and right panels).
Furthermore, indicative of absolute proteasome-dependent
degradation, peptide hydrolysis was completely prevented in
the presence of 20 µM epoxomicin (Figure 5(b), green curve,
left and right panels). Similar results were also obtained when
MP-45 and MP-46 precursor peptides were incubated under
the same experimental conditions (Figure 5(c)) and when KH-
52 was hydrolyzed by 20S immunoproteasomes alone or when
associated with PSME3 (Fig. S5B).
We then assessed the second hypothesis namely that
PSME3-dependant stimulation of the 20S proteasome leads to
complete degradation of MHC class I epitopes. In fact,
although binding of PSME3 did not result in significantly
increased rates of substrate hydrolysis (Figure 5(b,c)), it may
modify proteasome cleavage specificities to generate different
patterns of peptide products as already extensively demon-
strated for REGα/β36 Such a change in enzymatic properties
may potentially affect the formation of specific antigenic pep-
tides such as SIINFEKL. To test directly this possibility, pep-
tides released during KH-52 hydrolysis by equimolar amounts
of 20S with and without PSME3 were analyzed by tandemmass
spectrometry (MS/MS). Importantly, shorter peptides (repre-
senting the great majority of proteasomal products36,62,63 were
excluded to minimize false-positive identification and signals
originating from small chemical compounds and therefore
were not identified or quantified. In contrast, peptides with
the correct size to bind to MHC-I heterodimers (i.e., 8–10
mers) were accurately analyzed. Using this approach, we iden-
tified 52 different peptides from KH-52, ranging in length from
8 to 16 residues and derived from the entire sequence of the
substrate. Although MS/MS does not provide quantitative
information regarding the absolute abundance of the peptides
detected, it is possible to assess their relative amounts by
comparing the corresponding ion intensities measured in
sequential MS/MS analyses. Therefore, we used ion intensities
to quantify the relative amounts of single fragments generated
from KH-52 in both degradation reactions. Remarkably, this
analysis demonstrated that different amounts of peptide pro-
ducts are released by 20Sc and PSME3-20S (Figure 5(d)). Most
importantly, we demonstrated that the generation of
SIINFEKL was strikingly suppressed in the presence of
PSME3, as inferred by a two-log value reduction in its ion
intensity (Figure 5(e)). This important finding was subse-
quently confirmed by a cross presentation assay which demon-
strated that the mixture of peptide products generated during
KH-52 peptide precursor hydrolysis by PSME3-20S protea-
some was nearly unable to activate a SIINFEKL-specific T cell
hybridoma unlike the mixture of peptides released by 20S alone
(Figure 5(F)).
All these results demonstrate that the regulator PSME3 has
the capacity to modify the cleavage properties of the 20S
proteasome in the nuclear compartment in such a way that
PTP-derived MHC class I antigenic peptides are destroyed
rather than being correctly processed and released.
Knockout of PSME3 gene causes tumor growth defect
Given the overexpression of PSME3 in human cancer cell lines
compared to the human healthy MRC5 lung fibroblast cell line,
we decided to look at the PSME3 mRNA and protein levels in
the mouse MCA205 sarcoma cell line in comparison with the
mouse normal B6 skin fibroblast cell line. We observed by
qRT-PCR that PSME3 mRNA level was notably upregulated
in MCA205 tumor cell line compared to the B6 cell line (Fig.
S6A). Furthermore, we noticed an overexpression of PSME3
protein in MCA205 sarcoma cell line compared to B6 cell line
(Figure 6(a), upper panel). To evaluate whether the difference
in PSME3 expression in murine cell lines contributes to anti-
gen production and presentation, MCA205 murine sarcoma
and B6 skin fibroblast cell lines were transiently expressing the
Globin-SL8-intron construct and their ability to activate B3Z
hybridoma was assessed by T-cell assay. We observed that
antigen presentation in MCA205 sarcoma cancer cell line was
lower than that in the normal fibroblast cell line supporting our
previous results with the human cancer cell lines (Figure 6(a),
lower panel). To further depict the role of PSME3 in tumor-
igenicity and cancer immune response, we genetically deleted
PSME3 in the MCA205 sarcoma cancer cell line using the
CRISPR/Cas9 technology (Figure 6(b), upper panel and Fig.
S6B). The Cas9-PSME3 MCA205 clones MCA-c13, MCA-c19
andMCA-c21 and the MCA205WT cells were then transiently
transfected with the Globin-SL8-intron construct and their
ability to activate B3Z hybridoma was assessed by T-cell
assay. We observed that Cas9-PSME3 MCA205 clones induce
a stronger activation of B3Z hybridoma compared to the par-
ental murine cell line (Figure 6(b), lower panel). Subsequently,
we acid stripped cell surface class I molecules and measured the
recovery of surface class I expression. The Cas9-PSME3
MCA205 clone MCA-c13 does not show any increase in
MHC-I Kb molecules at the cell surface compare to the
MCA205 WT cancer cell line (Fig. S6C). Rather, a decrease
both in the steady-state level and in the recovery of MHC-
I molecules is observed in the Cas9-PSME3 MCA205 clone
while those cells elicit a better cancer immune response. This
result convincingly supports the idea that the effect of PSME3
on antigen presentation takes place earlier than the loading of
the antigenic peptides and the exporting steps of the MHC
class I peptide complex.
The proteasome regulator PSME3 has been reported to have
a specific effect on tumorigenicity. In fact, it has been shown that
PSME3 contributes to the proliferation and metastasis of differ-
ent cancer types. To gauge the effect of PSME3 on cancer
immune response and tumorigenicity in vivo, C57BL/6 mice
were subcutaneously injected into the flank with MCA205 WT
cells or with several Cas9-PSME3 MCA205 clones. As shown in
Figure 6(c) and in figure S6D (upper panels), the Cas9-PSME3
MCA205 clones lead to tumors smaller than the parental cell
line at day 20 after challenge. This result indicates that the loss of
PSME3 induces a decrease in the tumorigenicity of sarcoma
cells. To validate that this decrease in tumorigenicity was due,
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at least in part, to a specific activation of the cancer immune
response, as we observed in vitro, nude mice were subcuta-
neously injected with MCA205 cells or several Cas9-PSME3
MCA205 clones. We observed that the relative tumor growth
in Nude mice vs C57BL/6 mice was higher for the Cas9-PSME3
MCA205 clones than MCA205 WT (Figure 6(d) and Fig. S6D).
This difference suggests that the enhanced eradication of Cas9-
PSME3 MCA205 clones compared to MCA205 WT in immu-
nocompetent mice is partly mediated by the adaptive immune
system. PSME3 play therefore an important role in antigen
presentation, tumorigenicity and antitumor immune responses.
Discussion
This study describes for the first time a distinct and unexpected
role of the PSME3-proteasome complex, which proved to be
responsible for the degradation of MHC-I peptides in cancer.
Specifically, we demonstrate an inverse correlation between
PSME3 expression and MHC-I antigen presentation in can-
cers, thus revealing a new function of this regulator in blunting
immune responses by modulating the activity of the protea-
some processing pathway in vitro and in vivo.
In contradiction with our results, Barton et al. demon-
strated, approximately twenty years ago, that PSME3-/- mice
did not show notable impairment in antigen presentation after
viral infection.30 The only observed phenotypes reported so far
for PSME3-/- mice are a small reduction in the number of
specific CD8+ T lymphocytes and growth retardation.30,31 In
this study, we clearly demonstrate for the first time a specific
role for PSME3 inMHC-I antigen processing and presentation.
First, we show that PSME3 acts as a negative regulator of
MHC-I antigen presentation in cancer by destroying in vitro
and in cellulo MHC-I peptides generated during proteasomal
degradation of PTPs. Furthermore, our data suggest that over-
expression of PSME3 negatively affects cancer immune
response in vivo. Considering our results, it is therefore not
surprising that Barton et al. have not observed any effect on
antigen presentation in mice lacking PSME3. Indeed, we
observed a defect in MHC-I antigen presentation only in
cancer cell lines which naturally overexpress PSME3. The
knock-down of PSME3 in different cancer cell lines using
either siRNA, miRNA-7 overexpression, cisplatin treatment
or the CRISPR/Cas9 technology rescued the ability of the
tumor cells to activate CD8+ T cells in-vitro and enhanced
Figure 6. Knockout of PSME3 gene causes tumor growth defect. (a) The B6 fibroblast and MCA205 sarcoma cell lines were transfected with β-Glob-intron-SL8 constructs.
Cells were co-cultured with the SL8-specific CD8+T cell hybridoma (B3Z) for 16 h. Upper panel shows the protein level of PSME3 in the tumor cells assessed by Western
Blot (quantification relative to the housekeeping protein β-actin). Lower panel shows the relative level of antigen presentation in the tumor cells. (b) The MCA205
sarcoma cell line and the Cas9-PSME3 MCA205 clones MCAc13, MCAc19 and MCAc21 were transfected with the β-Glob-intron-SL8 construct for 48 h. The cells were then
co-cultured with the SL8-specific CD8 + T cell hybridoma (B3Z) for 16 h. Upper panel shows the protein level of PSME3 in the tumor cells assessed by Western Blot
(quantification relative to the housekeeping protein β-actin). Lower panel shows the relative level of antigen presentation in the tumor cells. (c) Tumor size in area of
sarcoma MCA205 WT and Cas9-PSME3 MCA205 clones subcutaneously inoculated into the right flank of immunocompetent C57BL/6 mice. Data are given as mean ±
SEM of 12 mice per group. (d) Tumor size in area of sarcoma MCA205 WT and Cas9-PSME3 MCA205 clones subcutaneously inoculated into the right flank of
immunodeficient Nu/Nu mice or immunocompetent C57BL/6 mice (left panel). Relative growth of MCA205 WT and Cas9-PSME3 MCA205 clones in immunodeficient Nu/
Nu mice compared to immunocompetent C57BL/6 mice. Data are given as mean ± SEM of 6 mice per group. *p <.05, **p <.01 (ANOVA with Tukey’s multiple
comparaison test comparing all groups).
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the antitumor response in vivo by inducing the presence of
tumor associated antigen from different sequences.
It is generally believed that only REGα/β in association with
the immunoproteasome can affect the production of MHC-I
epitopes. Strikingly, our results demonstrate a close correlation
between the expression of PSME3 and tumor immune evasion.
Thus, not only the heteroheptamer REGα/β plays a role in
antigen presentation but so does PSME3, in an opposite man-
ner. In fact, we demonstrated that knocking out of PSME3
could reduce the growth of MCA205 sarcoma tumors in
immunocompetent mice. However, when we performed the
same experiment in nude mice which are deficient in T cells
but not in B or innate immune cells, we did observe an
increased tumor growth of several Cas9-PSME3 MCA205
clones compared to the MCA205 WT cells that overexpress
PSME3. This experiment indicates that the knockout of PSME3
could induce the presentation of new PTP-MIPs that are
recognized by CD8+T cells and thus delay tumor growth.
Interestingly, a recent study reported that PSME3 can affect
MHC class I presentation by decreasing the expression levels of
immunoproteasomes through a molecular mechanism invol-
ving modulation of the JAK-STAT pathway obtained via
enhancement of proteasomal degradation of phosphorylated
STAT-3 in bone marrow-derived and splenic DC, MEF and
HeLa cells. However, in the mouse and human cell lines tested
in our study, we could not detect any major effect of PSME3 on
the expression levels of immunoproteasome in basal condi-
tions or under INFγ stimulation (Fig. S7). These findings,
therefore, suggest that different molecular mechanisms control
immunoproteasome expression in cells of diverse origin and
emphasize the importance of further studies to systematically
investigate the exact role of the JAK-STAT pathway in mod-
ulating cell-mediated class I immune responses in different cell
types and in physiological and pathological contexts. In this
regard, it is worth noting that the expression of immunopro-
teasome in tumor cells is extremely variable, without a general
rule but with large differences depending on the different types
of tumors analyzed.64,65
As mentioned above, many studies have reported that
PSME3 is overexpressed in several cancers.40–42 This overex-
pression constitutes a beneficial setting for tumors to prolifer-
ate and become metastatic. In fact, PSME3 was recently shown
to be involved in the degradation of some regulatory proteins.
For example, the cyclin-dependent kinase inhibitor p21 is
specifically degraded in an ATP- and ubiquitin-independent
process via the PSME3-proteasomal pathway.18 Furthermore,
two other cyclin-dependent kinases inhibitors, p16 and p14,
are reportedly degraded via the same pathway.17 Even more
importantly, PSME3 has been shown to be involved in the
MDM2-mediated p53 degradation process.20 These findings
demonstrate the important role of PSME3 in tumorigenicity
by regulating cell proliferation and apoptosis. In this study, we
demonstrate a new role for PSME3 in tumor growth and
development. Indeed, PSME3 overexpression not only pro-
motes cancer progression but it reduces the amount of poly-
peptides that can serve as MHC-I epitopes, thus impairing the
recognition of cancer cells by the immune system.
The REGα/β complex is mainly located in the cytoplasm,
while PSME3 is mostly a nuclear proteasomal regulator.15
PSME3 has been shown to be associated with the 20S protea-
some in nuclear speckles.22 Moreover, many reports have
demonstrated that the 20S proteasome and immunoprotea-
some are present in the nucleus and more specifically in clasto-
some structures.66 Considering that PTPs are produced by
a nuclear translation event, it is clearly more beneficial for
cells to process the different PTPs in the same compartment
where they are produced. Cancer cell stealth is also promoted if
TA-PTPs are rapidly destroyed where they are produced and
do not have a chance to be properly processed in the cytoplasm
and loaded on MHC I molecules. Therefore, by overexpressing
PSME3 in the nucleus where PTPs are located, cancer cells add
another layer of regulation to the immune response. Indeed, we
were able to restore a proper immune response against TA-
PTPs by manipulating the localization of PSME3 with the
ΔNLS construct. This identification of a specific site for TA-
PTP degradation reinforced our recent hypothesis that under
normal conditions peptides for the MHC-I presentation path-
way are produced and processed in the nucleus while under
abnormal conditions such as cancer development, the TA-
PTPs produced in the nucleus are no longer processed by the
standard 20S proteasome, the immunoproteasome or the
REGα/β-proteasomal complex but rather by the PSME3-
proteasome complex which minimizes the generation of
MHC-I epitopes.13,67–70
Although the heptameric REGα/β has been reported to
stimulate all three proteasomal activities,12 the effect of
PSME3 on proteasomal cleaving specificities appear to be
more complex and strictly related to the exact sequence of
the fluorogenic short peptides used to assess them.28 The
heptameric REGα/β regulator binds to 20S proteasome and
immunoproteasome and in this way enhances generation of
some, but not all, MHC-I epitopes.14 Two different explana-
tions might be proposed to explain the ability of PSME3 to
decrease PTP-dependent antigen presentation: PSME3 might
(i) inhibit PTP processing via the proteasome complex or (ii)
enhance the destruction by 20S proteasome of MHC-I epitopes
embedded in PTPs. Here, we propose that the binding of
PSME3 to the nuclear 20S proteasome stimulates the degrada-
tion, rather than the proper processing, of MHC-I antigenic
peptides by changing the peptidase activities of the 20S core
particle. In vitro degradation assays clearly showed that several
polypeptides (ranging in length between 45 and 53 residues)
with sizes and sequences corresponding to different PTPs are
efficiently hydrolyzed by PSME3-20S proteasomes at rates only
slightly lower than those obtained with REGα/β-20S particles.
These experiments rule out the possibility that PSME3, by
binding to 20S proteasome, may simply act as general inhibitor
of proteasomal degradation of PTPs. Interestingly, the same
kinetics of substrate hydrolysis were obtained when the poly-
peptide precursor was degraded by 20S immunoproteasomes
in the presence or absence of PSME3, which suggests that the
activator acts in a similar manner on the two proteasomal
species, although further studies will be required to clarify
this important point in greater detail. In line with the alter-
native hypothesis that PSME3 may induce destruction, rather
than proper processing, of specific antigenic peptides, MS
analysis demonstrated that 20S proteasome is able to efficiently
process and release the immunodominant epitope SIINFEKL
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embedded in the precursor peptide KH-52, corresponding to
the sequence of the β-globin intron region. Crucially, however,
when the precursor peptide KH-52 was degraded by the 20S
proteasome activated by PSME3, the generation of the immu-
nodominant epitope SIINFEKL was completely abolished.
Importantly, degradation assays were performed under condi-
tions that have previously been shown to allow generation of
individual peptides at linear rates for several hours.71
Therefore, although our MS semiquantitative analysis pre-
cluded the recognition of small peptides generated following
the fragmentation of SIINFEKL, the stimulation of proteaso-
mal peptidase activities, resulting in the destruction of the
antigenic peptide, appeared to be the more likely explanation
for the inability to detect the immunodominant epitope in the
presence of PSME3.
We recently reported that PTPs are a major source of MHC-
I antigenic peptides for the endogenous and exogenous path-
ways. In fact, by inhibiting PTP degradation by the proteasome
in tumor cell lines, we were able to increase the amounts of
unprocessed PTPs entering the exogenous pathway, resulting
in an increase in the activation of naïve CD8+ T cells.7,8 The
role we unveiled for PSME3 in the degradation of PTPs and
specifically its ability to inhibit the endogenous MHC-I antigen
presentation from TA-PTPs in tumors, leads to the hypothesis
that this mechanism might also affect PTP-dependent exogen-
ous MHC-I presentation. Indeed, by overexpressing PSME3 in
a CRISPR PSME3 knockout cell line, we showed that this cell
line was no longer able to induce the proliferation of CD8+
T cells via the exogenous pathway. Moreover, mutated and
ΔNLS-PSME3 constructs played a less active role in PTP
degradation, indicating that the main function of PSME3 was
to modulate the activity of the nuclear proteasomal complex,
with strong inhibitory consequences not only on MHC-I endo-
genous antigen presentation but also on MHC-I exogenous
pathway. Thus, we are driven to consider the PSME3-
dependent downregulation of MHC-I presentation in cancer
cells as evolutionary advantages allowing cancer cells to ensure
that TA-PTPs have no chances to enter the MHC-I exogenous
pathway and so to induce the proliferation of naïve CD8+
T cells.
Furthermore, it has been recently shown that retained
intron can be an important source of tumor neo-antigens.72
In a previous study we have reported that PTP-derived anti-
gens can arise from intronic but also from exonic sequences,
independently of mRNA stability or processing by the NMD
pathway.7 We demonstrated here that PSME3 affects the pre-
sentation of epitopes derived from both exonic and intronic
sequences. This suggests that PSME3 could degrade antigens
that arise from the canonical translation of exons and retained
introns in the cytoplasm in addition to the PTP-derived anti-
gens produced in the nuclear compartment. In a near future it
will be interesting to conduct a proteogenomic analysis to
gauge the effect of PSME3 downregulation on the presence of
exon- and intron-derived antigens in the MHC-I immunopep-
tidome of cancer cells.
In conclusion, the results of the present study, together with
those of previous studies investigating PSME3 functions, sup-
port the idea that tumor cells have acquired an established
system to positively regulate PSME3 expression enabling
them (i) to control the cell cycle arrest, (ii) to control their
proliferation and survival and most importantly (iii) to inhibit
the endogenous and exogenous MHC-I antigen presentation
pathways by specifically degrading TA-PTP-encoded MHC-I
epitopes. These results potentially serve as a starting point for
the development of new therapies aiming at decreasing intra-
cellular levels of PSME3 thus enhancing the production of
tumor-associated antigens and stimulating specific immune
responses against cancer.
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